These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 31584660)

  • 1. Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results.
    MacInnis RJ; Liao Y; Knight JA; Milne RL; Whittemore AS; Chung WK; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; McLachlan SA; Weideman PC; Nesci S; Friedlander ML; Glendon G; ; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB
    J Natl Cancer Inst; 2020 Apr; 112(4):418-422. PubMed ID: 31584660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Finch A; Poll A; Horsman D; Kim-Sing C; Scott J; Royer R; Sun P; Narod SA
    Br J Cancer; 2009 Jan; 100(2):421-5. PubMed ID: 19088722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
    Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
    Reiner AS; John EM; Brooks JD; Lynch CF; Bernstein L; Mellemkjær L; Malone KE; Knight JA; Capanu M; Teraoka SN; Concannon P; Liang X; Figueiredo JC; Smith SA; Stovall M; Pike MC; Haile RW; Thomas DC; Begg CB; Bernstein JL
    J Clin Oncol; 2013 Feb; 31(4):433-9. PubMed ID: 23269995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
    Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
    Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'.
    Kotsopoulos J; Metcalfe K; Alston J; Nikitina D; Ginsburg O; Eisen A; Demsky R; Akbari M; Zbuk K; Narod SA
    BMC Cancer; 2014 Mar; 14():221. PubMed ID: 24667084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
    Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
    Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
    Senst N; Llacuachaqui M; Lubinski J; Lynch H; Armel S; Neuhausen S; Ghadirian P; Sun P; Narod SA;
    Clin Genet; 2013 Jul; 84(1):43-6. PubMed ID: 23066998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
    Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.